The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
8
6
6
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis
Role: collaborator
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
Role: collaborator
Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer
Role: collaborator
A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
Role: collaborator
68Ga-PSMA PET in the Renal Cell Carcinoma
Role: collaborator
Plasma Exosome RNA to Diagnose Prostate Cancer
Role: collaborator
Submucosal Saline Injection Followed by Endoscopic Ultrasound
Role: collaborator
Evaluation of the Castor Single Branch Stent Graft in Treatment of Acute Aortic Syndrome
Role: collaborator
All 8 trials loaded